These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 26321362

  • 1. Identification of triazolo[4,5-b]pyrazine derivatives as hepatocyte growth factor receptor inhibitors through structure-activity relationships and molecular docking simulations.
    Dong M, Ren Y, Gao X.
    Bioorg Med Chem Lett; 2015 Oct 01; 25(19):4118-26. PubMed ID: 26321362
    [Abstract] [Full Text] [Related]

  • 2. 3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation.
    Balasubramanian PK, Balupuri A, Bhujbal SP, Cho SJ.
    J Biomol Struct Dyn; 2019 May 01; 37(8):2165-2178. PubMed ID: 30044205
    [Abstract] [Full Text] [Related]

  • 3. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
    Zhang L, Zhao J, Zhang B, Lu T, Chen Y.
    Eur J Med Chem; 2018 Apr 25; 150():809-816. PubMed ID: 29602036
    [Abstract] [Full Text] [Related]

  • 4. Studying the Binding Modes of Novel 2-Aminopyridine Derivatives as Effective and Selective c-Met Kinase Type 1 Inhibitors Using Molecular Modeling Approaches.
    Ye Q, Fu C, Li J.
    Molecules; 2020 Dec 24; 26(1):. PubMed ID: 33374386
    [Abstract] [Full Text] [Related]

  • 5. Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.
    Friedman M, Frank KE, Aguirre A, Argiriadi MA, Davis H, Edmunds JJ, George DM, George JS, Goedken E, Fiamengo B, Hyland D, Li B, Murtaza A, Morytko M, Somal G, Stewart K, Tarcsa E, Van Epps S, Voss J, Wang L, Woller K, Wishart N.
    Bioorg Med Chem Lett; 2015 Oct 15; 25(20):4399-404. PubMed ID: 26372653
    [Abstract] [Full Text] [Related]

  • 6. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
    Cui JJ, McTigue M, Nambu M, Tran-Dubé M, Pairish M, Shen H, Jia L, Cheng H, Hoffman J, Le P, Jalaie M, Goetz GH, Ryan K, Grodsky N, Deng YL, Parker M, Timofeevski S, Murray BW, Yamazaki S, Aguirre S, Li Q, Zou H, Christensen J.
    J Med Chem; 2012 Sep 27; 55(18):8091-109. PubMed ID: 22924734
    [Abstract] [Full Text] [Related]

  • 7. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
    Zhu J, Wu Y, Xu L, Jin J.
    Curr Comput Aided Drug Des; 2020 Sep 27; 16(1):17-30. PubMed ID: 31284868
    [Abstract] [Full Text] [Related]

  • 8. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
    Zhao F, Zhang J, Zhang L, Hao Y, Shi C, Xia G, Yu J, Liu Y.
    Bioorg Med Chem; 2016 Sep 15; 24(18):4281-4290. PubMed ID: 27448775
    [Abstract] [Full Text] [Related]

  • 9. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
    Zhao F, Zhang LD, Hao Y, Chen N, Bai R, Wang YJ, Zhang CC, Li GS, Hao LJ, Shi C, Zhang J, Mao Y, Fan Y, Xia GX, Yu JX, Liu YJ.
    Eur J Med Chem; 2017 Jul 07; 134():147-158. PubMed ID: 28411455
    [Abstract] [Full Text] [Related]

  • 10. Molecular modeling of exquisitely selective c-Met inhibitors through 3D-QSAR and molecular dynamics simulations.
    Yuan H, Zhuang J, Hu S, Li H, Xu J, Hu Y, Xiong X, Chen Y, Lu T.
    J Chem Inf Model; 2014 Sep 22; 54(9):2544-54. PubMed ID: 25181449
    [Abstract] [Full Text] [Related]

  • 11. Molecular modeling studies of atorvastatin analogues as HMGR inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations.
    Wang Z, Cheng L, Kai Z, Wu F, Liu Z, Cai M.
    Bioorg Med Chem Lett; 2014 Aug 15; 24(16):3869-76. PubMed ID: 25022881
    [Abstract] [Full Text] [Related]

  • 12. Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.
    Yan L, Zhang L, Zhang Y, Qiao X, Pan J, Liu H, Lu S, Xiang B, Lu T, Yuan H.
    J Biomol Struct Dyn; 2018 Jun 15; 36(8):2015-2031. PubMed ID: 28599617
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis and antibacterial activities of 5-(pyrazin-2-yl)-4H-1,2,4-triazole-3-thiol derivatives containing Schiff base formation as FabH inhibitory.
    Zhang F, Wen Q, Wang SF, Shahla Karim B, Yang YS, Liu JJ, Zhang WM, Zhu HL.
    Bioorg Med Chem Lett; 2014 Jan 01; 24(1):90-5. PubMed ID: 24332628
    [Abstract] [Full Text] [Related]

  • 14. Prediction of cytotoxic activity of a series of 1H-pyrrolo[2,3-b]pyridine derivatives as possible inhibitors of c-Met using molecular fingerprints.
    Damghani T, Mashayekh K, Pirhadi S, Firuzi O, Sharifi S, Edraki N, Khoshneviszadeh M, Avestan MS.
    J Recept Signal Transduct Res; 2019 Aug 01; 39(4):295-303. PubMed ID: 31658862
    [Abstract] [Full Text] [Related]

  • 15. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.
    Albrecht BK, Harmange JC, Bauer D, Berry L, Bode C, Boezio AA, Chen A, Choquette D, Dussault I, Fridrich C, Hirai S, Hoffman D, Larrow JF, Kaplan-Lefko P, Lin J, Lohman J, Long AM, Moriguchi J, O'Connor A, Potashman MH, Reese M, Rex K, Siegmund A, Shah K, Shimanovich R, Springer SK, Teffera Y, Yang Y, Zhang Y, Bellon SF.
    J Med Chem; 2008 May 22; 51(10):2879-82. PubMed ID: 18426196
    [Abstract] [Full Text] [Related]

  • 16. A computational strategy to understand structure-activity relationship of 1,3-disubstituted imidazole [1,5-α] pyrazine derivatives described as ATP competitive inhibitors of the IGF-1 receptor related to Ewing sarcoma.
    Guaitoli V, Alvarez-Ginarte YM, Montero-Cabrera LA, Bencomo-Martínez A, Badel YP, Giorgetti A, Suku E.
    J Mol Model; 2020 Aug 04; 26(8):222. PubMed ID: 32748063
    [Abstract] [Full Text] [Related]

  • 17. O-linked triazolotriazines: potent and selective c-Met inhibitors.
    Chen F, Wang Y, Ai J, Zhan Z, Lv Y, Liang Z, Luo C, Mei D, Geng M, Duan W.
    ChemMedChem; 2012 Jul 04; 7(7):1276-85. PubMed ID: 22539497
    [Abstract] [Full Text] [Related]

  • 18. Computational Simulation Study of Potential Inhibition of c-Met Kinase Receptor by Phenoxy pyridine Derivatives: Based on QSAR, Molecular Docking, Molecular Dynamics.
    Guo LY, Yang YL, Tong JB, Chang ZL, Gao P, Liu Y, Zhang YK, Xing XY.
    Chem Biodivers; 2024 Oct 04; 21(10):e202400782. PubMed ID: 38923279
    [Abstract] [Full Text] [Related]

  • 19. Antileishmanial potential of fused 5-(pyrazin-2-yl)-4H-1,2,4-triazole-3-thiols: Synthesis, biological evaluations and computational studies.
    Patil SR, Asrondkar A, Patil V, Sangshetti JN, Kalam Khan FA, Damale MG, Patil RH, Bobade AS, Shinde DB.
    Bioorg Med Chem Lett; 2017 Aug 15; 27(16):3845-3850. PubMed ID: 28693910
    [Abstract] [Full Text] [Related]

  • 20. Synthesis, antitumor evaluation and molecular docking studies of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives.
    Xu F, Yang ZZ, Jiang JR, Pan WG, Yang XL, Wu JY, Zhu Y, Wang J, Shou QY, Wu HG.
    Bioorg Med Chem Lett; 2016 Jul 01; 26(13):3042-3047. PubMed ID: 27184766
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.